NIH RePORTER
Cure8 research brief
Why This Matters
Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response restores benefit would inform a common real-world management question.
Who Should Pay Attention
Patients starting or considering p19/IL23 inhibitors (risankizumab, guselkumab, mirikizumab), clinicians who prescribe biologics for IBD, and researchers studying IBD biomarkers and therapeutic optimization.
Study Snapshot
Story typeClinical Reference
Evidence typeFunded research project
Study statusFunded
Source depthResearch project record
What To Know
This is an NIH-funded project summary (prospective cohort study) proposing to measure serum and mucosal cytokines related to IL23 signaling to identify biomarkers that predict response to p19 (IL23 p19 subunit) inhibitors and to test risankizumab dose intensification after loss of response.
The study will collect inflamed colon and ileum biopsies and serum before starting therapy, include an anti‑TNF comparator arm, and assess clinical and endoscopic outcomes at one year. The project also includes training and career-development components for the PI.
The summary describes planned measurement of cytokine concentrations (mucosal and serum), assessment of class-specificity versus anti‑TNF therapies, and an interventional evaluation of empiric dose intensification of risankizumab after loss of response. It does not report results; this is a funded research project describing aims and methods.
Keep In Mind
This record is a project summary describing planned research (prospective cohort) and training activities; it does not present study results. Biomarker and dose‑intensification aims are investigational and intended to guide future clinical practice only if supported by study findings.
Source Details
Review the original publication for the complete reporting, methods, and context.
Funded research project
Evidence type derived from source or registry metadata.
PublicationNIH RePORTER
AuthorsRahul S. Dalal
InstitutionBRIGHAM AND WOMEN'S HOSPITAL
Study typeFunded Research Project
Indexed viaNIH RePORTER
Source typeFunded research record
PublishedSep 1, 2026, 12:00 AM
Content availableResearch project record
Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases - K23DK146169 - $193,776
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
How Biologics Are Changing the Global Burden of Inflammatory Bowel Disease: A Review.
Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...